EATRIS in ACT EU Multi-stakeholder Platform Advisory Group

The ACT-EU initiative is a joint effort by the European Commission, the Heads of Medicines Agencies, and the European Medicines Agency to transform how clinical trials are initiated, designed, and run in the European Union. The aim is to foster innovation, quality, and efficiency in clinical research, and to better integrate it with the European health system.

The establishment of the Multi-stakeholder Platform (MSP) and its Advisory Group are part of the 11 priority actions (PA) identified in the Accelerating Clinical Trials in the EU (ACT EU) initiative. The MSP advisory group provides strategic and operational advice to the ACT EU programme. It comprises representatives from key stakeholder groups directly impacted by clinical trial-related activities in the EU and will meet regularly to build mutual trust and discuss key priorities.

During the inaugural meeting on 20 March 2024, Rosan Vegter (EATRIS’ Senior Rare Disease Innovation Officer) and Anton Ussi (Operations & Finance Director) were installed as permanent representatives of the Multi-stakeholder Platform Advisory Group (MSP AG). Participation in this group provides an important opportunity to identify priorities for the EATRIS community and the broader research community impacted by clinical trial activities in the EU, and by seamlessly integrating those into ACT EU’s initiatives, the MSP advisory group offers strategic and operational guidance to accelerate trials in the EU.


Open consultation

In this role, we seek to enhance the EU clinical trials landscape by collecting feedback through a survey from various academic stakeholders, including ERNs and academic institutions, and we look forward to your input.

Please find the link to the open consultation survey here

You can also get in contact with Rosan Vegter (rosanvegter@eatris.eu).

Useful links

For more information, visit this page: Accelerating stakeholder collaboration to enhance the clinical trials environment in the EU | European Medicines Agency (europa.eu)

Additional information about the ACT EU Initiative and the Multi-stakeholder Platform can be found here:

Contact

Rosan Vegter
Scientific Lead Rare Diseases and Regulatory Advisory